RecovryAI Earns FDA Breakthrough Device Status for Patient-Centered Clinical AI

RecovryAI has announced that its Virtual Care Assistants have received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). 

This designation is intended for devices that tackle serious medical conditions and show potential to enhance patient care. 

It also allows RecovryAI to engage with the FDA earlier in the development process while still adhering to stringent safety and reliability standards.

This achievement comes as RecovryAI emerges from stealth mode after more than two years of development and clinical testing. 

With over 80% of surgeries in the U.S. now performed as same-day procedures, patients often face the challenge of recovering at home during the most critical period—especially the first 72 hours post-surgery. 

During this time, complications can go unnoticed, instructions may be unclear, and clinicians have limited real-time oversight, increasing the risk of emergency visits, readmissions, or delays in care. 

Meanwhile, care teams frequently handle large volumes of routine patient inquiries, limiting their availability for higher-acuity cases.

RecovryAI’s VCAs address these gaps by extending post-operative care from the hospital to the home. 

The AI provides patients with personalized guidance based on clinical protocols and automatically alerts physicians when deviations occur, supplying complete context for timely interventions. 
The initial rollout targets patients undergoing total joint arthroplasty, with plans to expand to other surgical procedures.

The company is pursuing FDA clearance through a novel Class II pathway for patient-facing Software as a Medical Device (SaMD) and is conducting a multi-site pivotal clinical study, including sites like OrthoArizona and Mercy Medical Center, following promising pilot study outcomes.